FDA Class II Recall: H J Harkins Company's cGMP Deviations Impact Acetaminophen and Codeine Phosphate Supply
H J Harkins Company Inc dba Pharma Pac faced an FDA Class II recall for 9,000 units of Acetaminophen and Codeine Phosphate 300/30 mg tablets due to cGMP deviations. This terminated recall, initiated in 2020, underscores critical supply chain vulnerabilities in pharmaceutical repackaging. Procurement and regulatory teams must enhance due diligence for all partners, ensuring robust quality systems to mitigate disruption risks for essential opioid analgesics distributed in California and Arizona.
FDA Class II Recall: H J Harkins Company's cGMP Deviations for Acetaminophen and Codeine Phosphate
H J Harkins Company Inc dba Pharma Pac initiated a voluntary Class II recall (D-1246-2020) for 9,000 tablets of Acetaminophen and Codeine Phosphate 300/30 mg, a critical opioid analgesic. The recall, which commenced on April 15, 2020, and was officially terminated on February 14, 2024, stemmed from identified Current Good Manufacturing Practice (cGMP) deviations at their Grover Beach, California facility. This event highlights the persistent challenges in maintaining stringent quality control across all stages of the pharmaceutical supply chain, particularly for repackaging operations. For procurement directors, this incident underscores the imperative of comprehensive due diligence extending beyond the original manufacturer. While Aurobindo was the original manufacturer of the recalled Lot # ATP12ZT, Exp. 05/21, the cGMP deviations occurred during the repackaging process by H.J. Harkins Co., Inc. This means that even when sourcing from reputable original manufacturers, the quality and compliance of downstream repackers can introduce significant risk. Regulatory affairs heads must recognize that the FDA holds all entities in the supply chain accountable for cGMP adherence, irrespective of their specific role, necessitating robust quality agreements and oversight mechanisms with all partners handling drug products. The recall affected various bottle counts, from 10-count (NDC 52959-0003-10) to 60-count (NDC 52959-0003-60), indicating a broad impact on product packaging formats.
Operational Impact: H J Harkins Company's Grover Beach Repacking Facility
The recall originated from H J Harkins Company Inc dba Pharma Pac's facility at 1400 W Grand Ave Ste F, Grover Beach, CA 93433-4221. This facility serves as a repacker, a crucial but often overlooked link in the pharmaceutical supply chain. The distribution pattern for the recalled Acetaminophen and Codeine Phosphate tablets was limited to California and Arizona, suggesting a regional focus for this specific product line. While the recall is now terminated, the initial cGMP deviations at a repacking facility can still have significant commercial ramifications. For business development executives, understanding the operational scope and compliance history of regional repackers is vital for market penetration strategies and competitive intelligence. A recall, even if resolved, can impact a repacker's reputation and ability to secure future contracts. Procurement teams must assess not only the cGMP status of API manufacturers but also the quality systems of all downstream partners, including those involved in secondary packaging, labeling, and distribution. The Class II classification indicates that while the health consequences were not immediately life-threatening, the potential for temporary or reversible adverse effects necessitated the recall, emphasizing the importance of flawless operational execution at every stage to protect patient safety and maintain market trust.
Supply Chain Risk: Implications for Downstream Distributors in CA and AZ
The distribution of the recalled 9,000 tablets of Acetaminophen and Codeine Phosphate 300/30 mg was confined to California and Arizona. This regional scope, while not global, still represents a significant disruption for healthcare providers and pharmacies within these states relying on H J Harkins Company Inc dba Pharma Pac for this specific opioid analgesic. As a Schedule III controlled substance, the availability of Acetaminophen and Codeine Phosphate is critical for pain management, and any interruption can impact patient care. For supply chain VPs, this incident underscores the vulnerability introduced by regional suppliers if not adequately vetted. Even a localized recall can necessitate rapid re-sourcing and qualification efforts, leading to increased operational costs and potential stock-outs. Business development executives should note that such events can create opportunities for competitors with more robust supply chain resilience in these specific markets. Regulatory affairs heads must ensure that their distribution networks are not only compliant with federal regulations but also capable of swift and effective recall execution within specific state jurisdictions, minimizing patient exposure and regulatory penalties. The termination of the recall on February 14, 2024, indicates that the immediate product removal and corrective actions have been completed, but the lessons learned regarding regional supply chain integrity remain pertinent.
Mitigating Supply Disruption: Alternative Sourcing for Opioid Analgesics
Given the cGMP deviations leading to the recall of Acetaminophen and Codeine Phosphate 300/30 mg tablets by H J Harkins Company Inc dba Pharma Pac, procurement directors must proactively identify and qualify alternative suppliers to mitigate future supply disruptions for essential opioid analgesics. While the original manufacturer, Aurobindo, was not implicated in the repackaging cGMP deviations, relying on a single repacker for finished dosage forms introduces a single point of failure. Diversifying sourcing strategies is paramount, particularly for controlled substances where regulatory hurdles for new supplier qualification can be extensive. For procurement teams, this means actively seeking out other FDA-approved repackers or distributors with demonstrated cGMP compliance records. Geographic diversity in sourcing can also help insulate against regional supply chain issues. The qualification process for new suppliers of controlled substances is rigorous, involving facility audits, quality system assessments, and often, specific state and federal licensing requirements. This can entail qualification timelines ranging from 6 to 18 months, depending on the complexity and regulatory scrutiny. Business development executives should highlight their companies' multi-source strategies and robust supplier qualification programs as a competitive advantage. This incident reinforces the need for continuous supplier monitoring and risk assessment, ensuring that all partners, from API manufacturers to finished product repackers, meet stringent quality and regulatory standards to safeguard product availability.
Regulatory Compliance Landscape: Broader Industry Trends in cGMP Enforcement
While specific prior regulatory actions for H J Harkins Company Inc dba Pharma Pac are not detailed, this Class II recall due to cGMP deviations aligns with a broader industry trend of heightened FDA scrutiny on manufacturing and quality control. Recent parallel events in the life sciences sector, such as Real Clean Distribuciones SA de CV's hand sanitizer recall due to methanol contamination, AVKARE Inc.'s Dutasteride recall for impurity failures, and Teva's Metformin recall for NDMA contamination, all underscore persistent vulnerabilities in cGMP adherence and supply chain oversight. These incidents, ranging from high to medium severity, demonstrate that cGMP issues are not isolated but systemic across various product types and company roles. For regulatory affairs heads, this pattern necessitates a proactive and holistic approach to compliance. It is insufficient to merely react to specific warning letters or recalls; rather, companies must continuously review and enhance their quality management systems, internal audit programs, and supplier qualification processes to anticipate and prevent similar issues. Supply chain VPs should recognize that the FDA's focus extends beyond API manufacturing to encompass all stages, including repackaging and distribution. The financial and reputational costs associated with cGMP non-compliance, even for a terminated recall, can be substantial, impacting market share and investor confidence. Learning from these industry-wide trends is critical for maintaining a robust and resilient supply chain that meets evolving regulatory expectations.
Recall Resolution and Future Compliance Expectations
The termination of the Class II recall (D-1246-2020) for Acetaminophen and Codeine Phosphate 300/30 mg tablets on February 14, 2024, signals that H J Harkins Company Inc dba Pharma Pac has likely completed the necessary corrective actions to address the cGMP deviations and removed the affected 9,000 tablets from distribution. The period from recall initiation on April 15, 2020, to its termination, spanning nearly four years, highlights the FDA's thoroughness in ensuring that all issues are comprehensively resolved before closing a recall case. For regulatory affairs heads, this extended timeline underscores the significant resources and sustained effort required to manage and resolve regulatory actions. Companies must be prepared for prolonged scrutiny and demonstrate a robust commitment to quality system improvements. Business development executives should factor in the potential for such long-term engagements when evaluating partnerships with repackers or other third-party service providers. While the immediate threat of this specific recall is over, the underlying cGMP deviations serve as a critical reminder for all stakeholders in the pharmaceutical supply chain: continuous compliance, proactive risk management, and transparent communication with regulatory bodies are essential. Future FDA inspections will undoubtedly focus on the sustained effectiveness of the implemented corrective and preventive actions (CAPAs) at the Grover Beach facility, ensuring that similar cGMP lapses do not recur and that product quality and patient safety are consistently maintained.